Multiple Sclerosis — Regained Strength and Restored Independence
Secondary Progressive Multiple Sclerosis (SPMS)
Patient
Silvia Baistrocchi, 56 years
Origin
Italy
Diagnosis
Secondary Progressive Multiple Sclerosis (SPMS)
Treatment
May 2024, with booster infusions in subsequent months
Author
Dr. Uladzislau Tsvirko
Patient Background
Silvia Baistrocchi, a 56-year-old woman from Italy, has been living with secondary progressive multiple sclerosis (SPMS). Over time, the disease course led to advanced motor impairment, generalised muscle weakness, and increasing fatigue. As a result, she became wheelchair-dependent and experienced growing difficulty performing basic daily activities, with a notable reduction in physical endurance and autonomy.
Treatment Protocol
- •Intravenous infusion of allogeneic mesenchymal stem cells (MSCs)
- •Intranasal administration of MSCs and purified exosomes
- •Nebulised inhalation therapy with regenerative biofactors
- •Two additional MSC booster infusions administered in subsequent months
- •Integrated with ongoing structured rehabilitation programme
Reported Functional Changes
- •Increased muscle strength, particularly in the lower limbs
- •Improved endurance and tolerance during physiotherapy sessions
- •Regained ability to stand up from the wheelchair and take several assisted steps
- •Maintenance of functional gains despite a prolonged intestinal infection in December 2024
- •Faster-than-anticipated recovery following the infectious episode
- •Sustained improvement in daily autonomy, physical confidence, and quality of life
Video Observations
Follow-up and Ongoing Monitoring
Silvia remains under ongoing medical observation and continues structured physical therapy. Since her most recent booster treatment, no further functional deterioration has been reported. Clinical follow-up continues to focus on maintaining stability and supporting further functional adaptation.
Clinical Context
This case illustrates how a stage-adjusted, personalised regenerative medicine approach may support functional capacity and systemic resilience in patients with progressive multiple sclerosis. At BioCells Medical, treatment strategies are developed individually, with careful consideration of disease stage, neurological status, and rehabilitation goals, and are accompanied by continuous medical oversight.
Note: All observations reported in this case are based on post-treatment follow-up communication with the patient's family and clinical team. Individual results vary. This case does not constitute a clinical trial and should not be interpreted as a guarantee of outcome.